KOREA WHO
-
-
-
Chairman of the Board and CTO of AimedBio
Nam Do-hyun
Neurosurgeon-Owner Secures KRW 1.4 Trillion Boehringer Deal
-
Last Updated on Dec 11, 2025
-
Chairman of the Board and CTO of AimedBio
Life Summary
Nam Do-hyun is Chairman of the Board and CTO of AimedBio.
He is focusing on expanding technology transfer partnerships while also accelerating research and development of follow-on pipelines.
He was born in August 1963.
He graduated from Seoul National University College of Medicine and earned both his master’s and doctoral degrees in neurosurgery from Seoul National University Graduate School.
He previously served as Director of the Cancer Stem Cell Research Center at Samsung Medical Center and Head of the government-designated Leading Project Group for Intractable Cancer Research under the Ministry of Health and Welfare.
In 2018, he founded AimedBio, which develops antibody-drug conjugate-based therapeutics. While serving as Chairman of the Board, he stepped down from the CEO position and currently serves as chief technology officer (CT).
He is an owner-manager with a background as a neurosurgeon, having accumulated 30 years of experience in the field of brain tumors.
He was the first in Korea to establish a method to isolate and culture cancer stem cells from glioblastoma patients.
He has worked as a specialist at the Department of Neurosurgery at Samsung Medical Center, Professor in the Department of Neurosurgery at Sungkyunkwan University School of Medicine, Professor in the Department of Convergence Medical Science, an advisory member of the PSOC at the U.S. National Cancer Institute, and a full member of the National Academy of Medicine of Korea.
He has a strong interest in addressing unmet medical needs.
#NamDo-hyun #AimedBio #biotechnology #ADC #cancerresearch #glioblastoma #medicalinnovation #technologytransfer #neurosurgery #unmetmedicalneeds
He is focusing on expanding technology transfer partnerships while also accelerating research and development of follow-on pipelines.
He was born in August 1963.
He graduated from Seoul National University College of Medicine and earned both his master’s and doctoral degrees in neurosurgery from Seoul National University Graduate School.
He previously served as Director of the Cancer Stem Cell Research Center at Samsung Medical Center and Head of the government-designated Leading Project Group for Intractable Cancer Research under the Ministry of Health and Welfare.
In 2018, he founded AimedBio, which develops antibody-drug conjugate-based therapeutics. While serving as Chairman of the Board, he stepped down from the CEO position and currently serves as chief technology officer (CT).
He is an owner-manager with a background as a neurosurgeon, having accumulated 30 years of experience in the field of brain tumors.
He was the first in Korea to establish a method to isolate and culture cancer stem cells from glioblastoma patients.
He has worked as a specialist at the Department of Neurosurgery at Samsung Medical Center, Professor in the Department of Neurosurgery at Sungkyunkwan University School of Medicine, Professor in the Department of Convergence Medical Science, an advisory member of the PSOC at the U.S. National Cancer Institute, and a full member of the National Academy of Medicine of Korea.
He has a strong interest in addressing unmet medical needs.
#NamDo-hyun #AimedBio #biotechnology #ADC #cancerresearch #glioblastoma #medicalinnovation #technologytransfer #neurosurgery #unmetmedicalneeds